A carregar...
Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts
BACKGROUND: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor. Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event associated with bevacizumab therapy for advanced non-squamous non-small-cell lung cancer (NSCLC). METHODS: A panel of expert on...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3335247/ https://ncbi.nlm.nih.gov/pubmed/22056855 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdr463 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|